AA
NMRA icon

ALPS Advisors’s Neumora Therapeutics NMRA Stock Holding History

ALPS Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-114,371
Closed -$114K – 1049
2025
Q1 		$114K Sell
114,371
-16,273
-12% -$27.9K ﹤0.01% 977
2024
Q4 		$1.38M Buy
130,644
+12,478
+11% +$150K 0.01% 407
2024
Q3 		$1.56M Sell
118,166
-6,252
-5% -$72.9K 0.01% 397
2024
Q2 		$1.22M Buy
124,418
+16,709
+16% +$173K 0.01% 422
2024
Q1 		$1.48M Buy
107,709
+1,719
+2% +$27.8K 0.01% 402
2023
Q4 		$1.81M Buy
+105,990
New +$1.3M 0.01% 349

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ALPS Advisors's NMRA Position: Q2 2025 in Review

ALPS Advisors sold out of Neumora Therapeutics (NMRA) in Q2 2025, closing a stake of 114,371 shares — an estimated $114K sold.

ALPS Advisors first reported a position in NMRA in Q4 2023 and held it in 6 quarters. The position peaked at $1.81M in Q4 2023. 98 funds tracked by Wall St. Rank hold NMRA as of Q2 2025.

  • ALPS Advisors reported no remaining Neumora Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ALPS Advisors sold 114,371 Neumora Therapeutics shares in Q2 2025, an estimated $114K.
  • ALPS Advisors first reported a position in Neumora Therapeutics in Q4 2023 and held it in 6 quarters.
  • ALPS Advisors's Neumora Therapeutics position peaked at $1.81M in Q4 2023.
  • 98 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2025.

Based on ALPS Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.